Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1091088
Abstract: Hepatocellular carcinoma (HCC) is the most common liver cancer and one of the leading causes of cancer-related deaths in the world. Mono-immunotherapy and combination therapy with immune checkpoint inhibitors (ICIs) and multitargeted tyrosine kinase inhibitors… read more here.
Keywords: hepatocellular carcinoma; hcc; advanced development; biomarkers immunotherapy ... See more keywords